Abstract
The serotonin2C (5-HT2C) receptor has attracted a lot of attention owing to its role in appetite regulation, depression, obsessive-compulsive disorder (OCD), panic disorders, and substance abuse. This review summarizes nonpatent and patent literature up to November 2005 that deals with the synthesis and characterization of selective 5-HT2C receptor agonists and antagonists. Highlights on structure-activity relationships have been included, when possible.
Keywords: CYP1A2, mCPP, RO600175, anxiolytic, WAY-629, phenylpiperazine
Current Topics in Medicinal Chemistry
Title: Selective Agents for Serotonin2C (5-HT2C) Receptor
Volume: 6 Issue: 18
Author(s): Enza Lacivita and Marcello Leopoldo
Affiliation:
Keywords: CYP1A2, mCPP, RO600175, anxiolytic, WAY-629, phenylpiperazine
Abstract: The serotonin2C (5-HT2C) receptor has attracted a lot of attention owing to its role in appetite regulation, depression, obsessive-compulsive disorder (OCD), panic disorders, and substance abuse. This review summarizes nonpatent and patent literature up to November 2005 that deals with the synthesis and characterization of selective 5-HT2C receptor agonists and antagonists. Highlights on structure-activity relationships have been included, when possible.
Export Options
About this article
Cite this article as:
Lacivita Enza and Leopoldo Marcello, Selective Agents for Serotonin2C (5-HT2C) Receptor, Current Topics in Medicinal Chemistry 2006; 6 (18) . https://dx.doi.org/10.2174/156802606778522168
DOI https://dx.doi.org/10.2174/156802606778522168 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Topiramate and Other Anticonvulsants in the Treatment of Alcohol Dependence: A Clinical Review
CNS & Neurological Disorders - Drug Targets Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry Phosphoinositide 3-Kinase Gamma (PI3Kγ) Inhibitors for the Treatment of Inflammation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot topic: In Silico Approaches in G Protein-Coupled Receptors (GPCRs) Drug Discovery: Quo Vadis? (Executive Editor: Stefano Moro)]
Current Pharmaceutical Design Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on DNA & Gene Sequences Idarucizumab: What Should We Know?
Current Drug Targets Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid
Current Alzheimer Research HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design Editorial [Hot Topic: Perspectives in Psychopharmacological Neuroimaging (Executive Editor: Paolo Fusar-Poli)]
Current Pharmaceutical Design Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Current Pharmaceutical Design Formulation Strategies of Nano Lipid Carrier for Effective Brain Targeting of Anti-AD Drugs
Current Pharmaceutical Design Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders
Current Alzheimer Research PUFA for Prevention and Treatment of Dementia?
Current Pharmaceutical Design Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology Rationally Designed Multitarget Agents Against Inflammation and Pain
Current Medicinal Chemistry